I know this pharma stock was popular a couple of years ago because of its breakthrough with cancer treatments for aggressive, rare cancers that typically don't respond to available treatments. It recently was kicked back by the FDA and more research is required before approval, so it's back in clinical trials.
Unfortunately, my sister developed this exact rare cancer and I've been learning a lot about this treatment and I'm hopeful she'll be accepted into a clinical trial soon.
Of course, I went ahead and added it to my portfolio since it might be THE drug that changes how cancer is treated in the future. I'm wondering if anyone can share what they know about timelines for FDA approval and general DD.
Leave a Reply